Publications (81) Publications de Francisco Javier Bachiller Corral

2024

  1. Agreement between local and central anti-synthetase antibodies detection: results from the Classification Criteria of Anti-Synthetase Syndrome project biobank

    Clinical and experimental rheumatology, Vol. 42, Núm. 2, pp. 277-287

  2. Characterization of flare-ups and impact of garetosmab in adults with fibrodysplasia ossificans progressiva: A post hoc analysis of the randomized, double-blind, placebo-controlled LUMINA-1 trial

    Journal of Bone and Mineral Research, Vol. 39, Núm. 10, pp. 1486-1492

  3. Quality of life of patients with rheumatic diseases

    Reumatologia Clinica, Vol. 20, Núm. 2, pp. 59-66

  4. Successful treatment of AA amyloidosis with tocilizumab, resulting in the disappearance of amyloid deposits: a case-based review

    Egyptian Rheumatology and Rehabilitation, Vol. 51, Núm. 1

  5. Toward Telemonitoring in Immune-Mediated Inflammatory Diseases: Protocol for a Mixed Attention Model Study

    JMIR Research Protocols, Vol. 13, Núm. 1

2023

  1. Evaluating remission and low disease activity from the perspective of the patient with axial spondyloarthritis: The cross-sectional ConREspAx study

    Joint Bone Spine, Vol. 90, Núm. 2

  2. Garetosmab in fibrodysplasia ossificans progressiva: a randomized, double-blind, placebo-controlled phase 2 trial

    Nature Medicine, Vol. 29, Núm. 10, pp. 2615-2624

  3. Myositis autoantibodies detected by line blot immunoassay: clinical associations and correlation with antibody signal intensity

    Rheumatology International, Vol. 43, Núm. 6, pp. 1101-1109

  4. Severe COVID-19 in patients with immune-mediated rheumatic diseases: A stratified analysis from the SORCOM multicentre registry

    Modern rheumatology, Vol. 34, Núm. 1, pp. 97-105

2022

  1. Clinical spectrum time course in non-Asian patients positive for anti-MDA5 antibodies

    Clinical and experimental rheumatology, Vol. 40, Núm. 2, pp. 274-283

  2. Low Positivity Rate of Anti-SARS-CoV-2 IgG in Unvaccinated Patients With Rheumatic Diseases Treated With Rituximab

    Journal of Clinical Rheumatology, Vol. 28, Núm. 8, pp. 424-428

  3. Retention rate of secukinumab in psoriatic arthritis: Real-world data results from a Spanish multicenter cohort

    Medicine (United States), Vol. 101, Núm. 36, pp. E30444

2021

  1. Artritis reumatoide: Tratamiento

    Medicine: Programa de Formación Médica Continuada Acreditado, Serie 13, Núm. 30, pp. 1681-1693

  2. Cardiovascular mortality and cardiovascular event rates in patients with inflammatory rheumatic diseases in the CARdiovascular in rheuMAtology (CARMA) prospective study-results at 5 years of follow-up

    Rheumatology (Oxford, England), Vol. 60, Núm. 6, pp. 2906-2915

  3. Clinical characteristics and COVID-19 outcomes in a regional cohort of pediatric patients with rheumatic diseases

    Pediatric Rheumatology, Vol. 19, Núm. 1

  4. Development of Iatrogenic Cushing Syndrome after Peri-articular Glucocorticoid Injection in an Human Immunodeficiency Virus Patient on Protease Inhibitor Therapy

    Journal of Clinical Rheumatology

  5. Espondiloartritis

    Medicine: Programa de Formación Médica Continuada Acreditado, Serie 13, Núm. 29, pp. 1599-1610

  6. Factors associated with COVID-19-related death in people with rheumatic diseases: Results from the COVID-19 Global Rheumatology Alliance physician-reported registry

    Annals of the Rheumatic Diseases, Vol. 80, Núm. 7, pp. 930-942

  7. Otras espondiloartritis

    Medicine: Programa de Formación Médica Continuada Acreditado, Serie 13, Núm. 29, pp. 1635-1648

  8. Protocolo diagnóstico y terapéutico del síndrome seco

    Medicine: Programa de Formación Médica Continuada Acreditado, Serie 13, Núm. 30, pp. 1730-1734